Additionally, GLP-1 drugs have been shown to lower the risk of major cardiovascular events, such as heart attacks and strokes, in patients with type 2 diabetes, regardless of their impact on blood sugar levels
Gastric bypass: Is invasive and irreversible Requires lifelong nutritional monitoring Carries surgical and long-term risks GLP-1 medications: Can cause GI side effects May not be tolerated by everyone Require long-term commitment There is no single right answer only the right plan for the individual
10.3748/wjg.v24.i48.5462 17 DuzelA.VlainicJ.AntunovicM.MalekinusicD.VrdoljakB.SamaraM.et al (2017)
Medical science has made such tremendous progress that there is hardly a healthy human left. Aldous Huxley GLP-1 Agonists at a Glance First-Generation (Short-Acting) Exenatide Byetta Lixisenatide Adlyxin / Lyxumia Second-Generation (Long-Acting) Exenatide ER Bydureon (weekly, now discontinued in some markets) Liraglutide Victoza (diabetes), Saxenda (obesity) Dulaglutide Trulicity Semaglutide Ozempic (diabetes), Wegovy (obesity), Rybelsus (oral) Dual Agonist (GIP + GLP-1) Tirzepatide Mounjaro (diabetes), Zepbound (obesity) Triple or Combination Agonists (In Development) Retatrutide Triple agonist (GLP-1 + GIP + glucagon) CagriSema Combination of cagrilintide + semaglutide (GLP-1 + amylin analog) Orforglipron Oral, non-peptide GLP-1 receptor agonist (Eli Lilly) Danuglipron Oral small-molecule GLP-1 agonist (Pfizer) Efinopegdutide GLP-1/glucagon dual agonist (Merck/Biocon) AMG133 GLP-1 + GIP receptor modulator (Amgen)
Can I take PT-141 right after a big meal
